13 min read
5.0
35

Bone Loss in Menopause: How Fast It Happens, When It Peaks, and What Protects Your Bones

How fast bone loss happens across the menopause transition, when it peaks, how it's tested, and what protects bone — treatment included.

Jane Smorodnikova
Founder & CEO
Kseniia Iaroslavtseva
COO & Strategy team teamlead
Anna Elitzur
Medical Advisor
Menopause speeds up bone loss because falling estrogen tilts bone remodeling toward breakdown. The loss isn't steady: it accelerates in late perimenopause and is fastest in the transmenopause window (about a year before the final period through ~2 years after), then slows to an age-related rate. Osteoporosis is diagnosed with a DXA scan (T-score) and estimated with FRAX; bone is protected by a layered plan — calcium/vitamin D, weight-bearing and resistance exercise, fall prevention, and medication classes when fracture risk is high. A wearable cannot measure bone.

Short Answer

Menopause can speed up bone loss because falling estrogen makes your bone-remodeling system tilt toward breakdown: your body removes old bone faster than it can replace it. The pace is not flat. In SWAN data, bone mineral density loss became most pronounced around the final menstrual period — starting about a year before it and staying fastest through roughly two years after it — and then continued more slowly with age. (pmc.ncbi.nlm.nih.gov)

Osteoporosis is diagnosed with a DXA bone-density scan, usually focused on fracture-prone sites like the hip and spine. A wearable can support the surrounding plan — movement, consistency, recovery, fall-risk habits — but it cannot measure bone density or diagnose osteoporosis. Protecting bone is layered: enough bone-supporting nutrition, regular weight-bearing and balance work, and medication when your clinician decides your fracture risk is high enough to need it. (niams.nih.gov)

Bone loss in menopause at a glance

Menopause can speed up bone loss because estrogen is one of the signals that keeps bone breakdown in check. When estrogen falls, osteoclasts — the cells that resorb old bone — become more active, and bone formation often cannot fully catch up. That is why the balance shifts from steady remodeling toward net loss. Menopause can also sit inside a broader body-composition shift, in which muscle and bone decline together — a loss of lean mass alongside bone mineral density that raises the risk of both sarcopenia and osteoporosis.

The fastest window is usually not “all of menopause.” In SWAN, bone mineral density loss was greatest from about 1 year before the final menstrual period through about 2 years after it — the transmenopause window. After that, loss often slows, but it does not simply stop. (pubmed.ncbi.nlm.nih.gov)

The speed depends on the site. In SWAN data, late perimenopause and early postmenopause were linked with roughly 1.8–2.3% bone loss per year in the lumbar spine and about 1.0–1.4% per year at the hip in summary analyses; the original SWAN paper reported average losses of about 1.6% per year at the spine and 1.0% per year at the hip in late perimenopause, rising to about 2.0% and 1.4% per year in postmenopause. In plain English: spine loss tends to show up faster because the spine is rich in trabecular bone, which is more metabolically active. (pmc.ncbi.nlm.nih.gov)

Across the early postmenopausal years, commonly cited estimates suggest women may lose about 25%–30% of trabecular bone and 10%–15% of cortical bone over the first 5–10 years after menopause, then age-related loss continues more slowly — often described as about 0.5% per year. These are population-level estimates, not a personal forecast; your baseline bone mass, body weight, medications, smoking, nutrition, strength, falls risk, and medical history all matter. (pmc.ncbi.nlm.nih.gov)

Bone loss is checked with a DXA scan, which reports bone mineral density as a T-score in postmenopausal women. A T-score of −2.5 or lower is the standard osteoporosis threshold, while FRAX adds clinical risk factors to estimate fracture risk — because fracture risk is bigger than density alone. (ncbi.nlm.nih.gov)

Yes, menopause-related bone loss can be treated. The base is not glamorous, but it matters: enough protein, calcium and vitamin D, resistance or weight-bearing exercise that is safe for you, fall prevention, not smoking, and avoiding heavy alcohol. If fracture risk is higher, a clinician may add medication — the choice depends on your DXA results, fracture history, FRAX risk, age, other conditions, and preferences. (niams.nih.gov)

What happens to bone in menopause

Your skeleton is not fixed. It is living tissue in constant renovation: osteoclasts clear away old or damaged bone, osteoblasts build new bone, and estrogen helps keep those two jobs in balance. One way it does that is by restraining RANKL signaling — the “go” signal that helps osteoclasts form, survive, and resorb bone. When estrogen falls during the menopause transition, that brake weakens. More bone can be broken down than rebuilt in the same remodeling cycle, so bone mineral density drops and the inner structure of bone can become less sturdy. This is why menopause is not just another birthday for your skeleton: for many women, osteoporosis starts to develop around the years just before menopause, and low estrogen after menopause is a recognized risk factor for bone loss. It is also why the muscle-bone connection matters here: as women age through menopause, lean muscle mass and bone mineral density tend to decline together, which raises the risk of both sarcopenia and osteoporosis. (pubmed.ncbi.nlm.nih.gov)

A few plain definitions, because they run through the rest of this page: perimenopause is the transition of shifting hormones before periods stop; the final menstrual period (FMP) is your last-ever period, confirmed in hindsight after 12 period-free months; postmenopause is everything after that transition. On a bone scan, osteopenia means low bone mass — a T-score between -1 and -2.5 — and osteoporosis means bone density is low enough to raise fracture risk, often a T-score of -2.5 or lower. (medlineplus.gov)

The timeline: when bone loss speeds up — and slows down

The most useful thing to understand about menopause and bone is that the loss is not a slow, even trickle. In early perimenopause, bone density may look almost unchanged. Then the curve bends. Loss accelerates in late perimenopause, and the sharpest drop tends to cluster around the final menstrual period, or FMP: about 1 year before the FMP through about 2 years after it. SWAN researchers describe that high-loss window as the transmenopause. After that, the pace usually eases, but it does not simply stop; it settles into a slower, longer age-related decline. (pubmed.ncbi.nlm.nih.gov)

Menopause stageWhat's happening to boneApproximate rate
Early perimenopauseLittle measurable change yet; your cycle may be changing, but bone loss has not usually hit its steep phase.roughly stable in SWAN’s early perimenopause data (pubmed.ncbi.nlm.nih.gov)
Late perimenopause (~1–2 yr before FMP)Loss accelerates as estrogen signaling becomes less reliable and bone resorption starts outpacing rebuilding.lumbar spine down about 1.8–2.3%/yr; hip about 1.0–1.4%/yr in SWAN-based summaries (pmc.ncbi.nlm.nih.gov)
Transmenopause (yr before FMP → ~2 yr after)Fastest bone loss. This is the vulnerable window when the curve is steepest, even if you feel mostly “fine.”greatest rate and cumulative loss from 1 year before through 2 years after FMP (pubmed.ncbi.nlm.nih.gov)
Early postmenopause (first several years)Rapid cumulative loss can continue before the curve flattens. Trabecular bone — the spongier bone inside the spine and ends of long bones — is hit especially hard.rapid postmenopausal phase is often described as lasting about 4–8 years, with roughly 20–30% trabecular and 5–10% cortical loss attributed to that phase in the Surgeon General’s bone health report (ncbi.nlm.nih.gov)
Later postmenopauseLoss slows toward the background aging pattern, but it continues, which is why fracture risk can keep rising with age.commonly cited slower loss is about 0.2–0.5%/yr after the rapid menopause-related phase (ncbi.nlm.nih.gov)

The practical takeaway: the years right around your last period are when bone is most vulnerable, which is exactly when it is worth knowing your numbers. A DXA scan measures bone density, and the result is usually reported as a T-score; that number helps show whether your bones are in the healthy range, osteopenia range, or osteoporosis range. (my.clevelandclinic.org)

How much bone you actually lose — and why it matters

The scary part of menopause bone loss is not that your skeleton suddenly “empties out.” It is that the pace changes fast. In SWAN, bone mineral density loss was greatest from 1 year before the final menstrual period through 2 years after it — the transmenopause window. Over the full 10-year observation period, lumbar spine BMD fell by 10.6%, with 7.38% of that loss happening during transmenopause; femoral neck BMD fell by 9.1%, with 5.8% happening in that same short window. Another SWAN analysis put the rapid-loss years at roughly 1.8–2.3% per year in the spine and 1.0–1.4% per year in the hip; if that pace continues for 5 years, the average loss is about 7–10% at the spine and 5–7% at the hip. Those are not cosmetic numbers. They are changes in the structure that helps bone absorb force. (pubmed.ncbi.nlm.nih.gov)

Trabecular bone — the spongy, honeycomb-like bone inside places such as the vertebrae — tends to show the earliest damage because it remodels faster than cortical bone, the denser outer shell. That is why spine measurements often move early: the lumbar spine is rich in trabecular bone, and trabecular architecture can thin, perforate, and lose connectivity before you feel anything. The commonly cited upper-end estimate is that women can lose up to about a quarter of trabecular bone mass across the acute postmenopausal years, followed by slower ongoing decline; cortical loss is usually slower at first, but it still matters later because cortical bone makes up most of the skeleton. (pmc.ncbi.nlm.nih.gov)

This matters because bone loss is quiet until it is not. In U.S. NHANES 2017–2018 data, 51.5% of women age 50 and older had low bone mass at the femur neck or lumbar spine, and 19.6% had osteoporosis at one or both of those sites. Osteoporosis-related fractures most often involve the hip, wrist, or spine; MedlinePlus notes that about half of women over 50 will have a hip, wrist, or vertebral fracture during their lifetime. So the goal is not to panic over a percentage point on a scan. It is to catch the fast-loss window early enough that you and your clinician can protect strength, balance, and fracture resistance before a fall, cough, or awkward bend becomes the first sign something changed. (cdc.gov)

Who loses more (risk factors)

Some women lose bone faster because their bones start the menopause transition with less “reserve,” and some lose faster because another stressor is pushing bone breakdown ahead of rebuilding. A clinician will look at the whole pattern: early menopause or having the ovaries removed at a younger age; low body weight or a small frame; a parent or sibling with osteoporosis, especially a parent who fractured a hip; smoking; heavy alcohol use; low calcium or vitamin D intake; long stretches of inactivity; long-term glucocorticoid steroid use; and medical conditions that can affect hormones, absorption, or inflammation, such as an overactive thyroid, celiac disease, and rheumatoid arthritis. (mayoclinic.org)

These are not boxes to tick for self-diagnosis. They are reasons to bring the question to a clinician earlier — especially if you are under 65 and wondering whether a bone density test makes sense. Bone mineral density testing is used to diagnose bone loss, estimate future fracture risk, and guide next steps; risk factors such as early menopause, low body weight, thyroid imbalance, rheumatoid arthritis, long-term corticosteroid use, tobacco use, heavy alcohol use, and strong family history can make that conversation more urgent. (medlineplus.gov)

How bone loss is measured

You can’t feel bone thinning as it happens, so it has to be measured, not guessed. The usual test is a DXA scan — you may also see it written as DEXA — which estimates bone mineral density and reports it as a T-score. A T-score above −1.0 is usually considered normal; a score from about −1.0 to −2.5 is called low bone mass or osteopenia; and −2.5 or lower meets the bone-density definition of osteoporosis. That number matters because lower density usually means less mineral “scaffolding” inside the bone, but it is still only one part of fracture risk: your age, prior fractures, medications, falls, smoking, alcohol use, body weight, and family history can change the picture. (ncbi.nlm.nih.gov)

For that bigger picture, clinicians often use FRAX, a risk calculator that estimates your chance of a hip fracture and a major osteoporotic fracture over the next 10 years. FRAX can be run with or without bone-density information, so it is useful before a scan when a clinician is deciding whether DXA is worth doing now rather than later. (pmc.ncbi.nlm.nih.gov)

On timing, the current USPSTF recommendation is straightforward for age: women 65 and older should be screened for osteoporosis. If you are postmenopausal and younger than 65, the decision is earlier and more personal: screening is recommended when clinical risk assessment suggests you are at increased fracture risk. Older USPSTF-based materials commonly cited a FRAX 10-year major osteoporotic fracture risk of 9.3% as the benchmark — roughly the risk of a 65-year-old White woman with no additional risk factors — but newer USPSTF evidence discussions describe 8.4% as the updated 2018 benchmark and the 2025 recommendation does not require one fixed FRAX cutoff for everyone. In practice, that means your clinician should look at your risk factors and not just your birthday. (pubmed.ncbi.nlm.nih.gov)

Treatment and protection

Protecting bone in menopause is layered. First comes the foundation your bones use every day: enough calcium and vitamin D to mineralize bone, regular weight-bearing and resistance (strength) exercise to keep bone under healthy load, balance work to lower fall risk, not smoking, and keeping alcohol moderate. Food usually comes first for calcium and vitamin D; supplements are a clinician conversation, especially if your diet, labs, medications, kidney health, or fracture risk make the answer less straightforward. (medlineplus.gov)

When fracture risk is high, clinicians may add medication. Think of the options below as “what job this class is meant to do,” not as a treatment plan. The right choice depends on your DXA results, fracture history, age, time since menopause, other conditions, medication risks, and what you can realistically take consistently. It is a clinician’s decision, and patient preferences should be part of that decision. (pubmed.ncbi.nlm.nih.gov)

Medication classExamplesWhat it's for
Menopausal hormone therapy (estrogen ± progestin)Can prevent menopause-related bone loss and fracture; benefit-risk, timing, route, duration, and whether progestin is needed are individualized. (pubmed.ncbi.nlm.nih.gov)
SERMsraloxifene, bazedoxifeneAct estrogen-like on some tissues, including bone; raloxifene is FDA-approved for prevention and treatment of osteoporosis in postmenopausal women. (accessdata.fda.gov)
Bisphosphonatesalendronate, risedronate, ibandronate, zoledronateAntiresorptive medicines that slow bone breakdown; guidelines commonly use them as initial pharmacologic treatment for many postmenopausal women with osteoporosis. (pubmed.ncbi.nlm.nih.gov)
RANKL inhibitordenosumabAntiresorptive medicine given by injection; used for postmenopausal osteoporosis when fracture risk is high or other therapies are not appropriate or tolerated. (accessdata.fda.gov)
Anabolic (bone-building) agentsteriparatide, abaloparatide, romosozumabUsed for high or very high fracture risk; these medicines are meant to build bone, and some guidelines reserve them for very high-risk situations or specific sequences of care. (pubmed.ncbi.nlm.nih.gov)

There are no doses in this article. None of these medications should be started, stopped, paused, or switched without a clinician, because stopping or changing bone-active therapy at the wrong time can leave you unprotected. (pmc.ncbi.nlm.nih.gov)

When to see a doctor

Talk with a clinician about whether it’s time for a DXA bone-density scan if you’re 65 or older; current USPSTF guidance recommends osteoporosis screening for women 65+ and for postmenopausal women under 65 when clinical fracture risk is increased. Bring it up sooner if menopause came early or was triggered by removal of both ovaries, because more years with low estrogen can raise osteoporosis risk. (pubmed.ncbi.nlm.nih.gov)

Don’t wait for a routine visit if your body is giving possible fracture clues: you’ve lost height, your posture is becoming stooped, you develop sudden or worsening back pain, or you break a bone after a small fall or minor stress that shouldn’t usually cause a fracture. Osteoporosis can be silent until a bone breaks, and these signs can mean the spine or another bone has already weakened, so they deserve prompt evaluation. (my.clevelandclinic.org)

How Welltory fits

Welltory doesn’t measure bone mineral density, and it can’t detect, diagnose, or rule out bone loss or osteoporosis. That job belongs to bone-density testing — most often DXA/DEXA — which measures mineral content in bone and is used to diagnose osteopenia and osteoporosis and estimate future fracture risk. (medlineplus.gov)

Where a wearable can help is the day-to-day layer around bone-protective habits. Bones respond to load, but the load has to keep showing up: walking, stair climbing, resistance work, balance work, the kinds of sessions that ask your muscles and skeleton to do real work without pushing you into a boom-and-bust cycle. Weight-bearing and strength exercises are commonly recommended to help maintain bone strength, support posture and balance, and lower fall risk — and consistency is where tracking can be useful. (mayoclinic.org)

Use Welltory as a habit mirror, not a bone scan. It can help you notice whether your strength and weight-bearing routines are actually happening, whether poor sleep or high stress is making recovery harder, and whether you may need an easier day so you can keep training next week instead of stopping for two. In other words: Welltory can support the behaviors that help protect bone, but it never measures the bone itself.

How we made it

We created this article with support from AI tools, then the Welltory editorial team edited it for clarity, checked the facts against reliable medical sources, and sent it for medical review before publication. You can read more about how we use AI and protect medical accuracy in our [Editorial & AI Policy].

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

This article is for educational purposes only and does not replace medical diagnosis or treatment. Osteoporosis is confirmed with a bone-density (DXA) scan, not by symptoms, and a wearable cannot measure bone. Only a qualified clinician can interpret your fracture risk and decide whether medication is appropriate — never start, stop, or adjust bone medication on your own.

Was this helpful?

Ask AI for a summary of page

ChatGPTGeminiClaudePerplexityGrok

Written by Jane Smorodnikova

The founder and CEO of Welltory. A recognized tech leader with two Master's degrees and experience at MIT, she has scaled Welltory to over 17 million users.

Written by Kseniia Iaroslavtseva

She reviews scientific research and turns it into structured, readable insights.

Reviewed by Anna Elitzur

With her medical degree, Anna reviews Welltory's health content for medical accuracy and alignment with current clinical guidelines and research.

References

  1. 18160467 / 2266953 — Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of Women — SWAN data on BMD change across menopause stages. https://pmc.ncbi.nlm.nih.gov/articles/PMC2266953/
  2. 3198834 — Bone Loss Across the Menopausal Transition — SWAN overview of bone loss timing across the menopause transition. https://pmc.ncbi.nlm.nih.gov/articles/PMC3198834/
  3. 21976317 — Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from SWAN — transmenopause timing, cumulative spine/femoral-neck loss, and deceleration after the rapid window. https://pubmed.ncbi.nlm.nih.gov/21976317/
  4. 3920744 — Bone and the Perimenopause — SWAN-based annual loss rates for lumbar spine and hip in late perimenopause. https://pmc.ncbi.nlm.nih.gov/articles/PMC3920744/
  5. NCBI Bookshelf — Bone Health and Osteoporosis: A Report of the Surgeon General — rapid postmenopausal bone-loss phase and trabecular/cortical bone-loss estimates. https://www.ncbi.nlm.nih.gov/books/n/rptosteo/pdf/
  6. 5643776 — Primary osteoporosis in postmenopausal women — menopause-related and age-related phases of postmenopausal bone loss. https://pmc.ncbi.nlm.nih.gov/articles/PMC5643776/
  7. CDC NCHS Data Brief No. 405 — Osteoporosis or Low Bone Mass in Older Adults: United States, 2017–2018 — U.S. prevalence of osteoporosis and low bone mass in adults 50+. https://www.cdc.gov/nchs/products/databriefs/db405.htm
  8. MedlinePlus — Osteoporosis — patient-facing overview of osteoporosis, common fracture sites, risk factors, and prevention. https://medlineplus.gov/osteoporosis.html
  9. MedlinePlus Medical Encyclopedia — Osteoporosis — fracture burden and screening summary. https://medlineplus.gov/ency/article/000360.htm
  10. MedlinePlus — Bone Density Scan — DXA/DEXA purpose and interpretation basics. https://medlineplus.gov/lab-tests/bone-density-scan/
  11. NCBI Bookshelf — Screening for Osteoporosis to Prevent Fractures: Evidence Review for the USPSTF — DXA, T-score threshold, FRAX context, and treatment thresholds. https://www.ncbi.nlm.nih.gov/books/NBK611357/
  12. 39808425 — Screening for Osteoporosis to Prevent Fractures: USPSTF Recommendation Statement — current USPSTF screening recommendation for women 65+ and postmenopausal women under 65 at increased risk. https://pubmed.ncbi.nlm.nih.gov/39808425/
  13. NCBI Bookshelf — Osteoporosis in Females — WHO T-score categories for normal bone density, osteopenia, and osteoporosis. https://www.ncbi.nlm.nih.gov/books/NBK559156/
  14. 30907953 — Pharmacological Management of Osteoporosis in Postmenopausal Women: Endocrine Society Clinical Practice Guideline — pharmacotherapy principles and treatment classes. https://pubmed.ncbi.nlm.nih.gov/30907953/
  15. 10885682 — Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: ACP Living Clinical Guideline — bisphosphonates, denosumab, romosozumab, teriparatide, and sequencing. https://pmc.ncbi.nlm.nih.gov/articles/PMC10885682/
  16. 34448749 — Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society — screening, prevention, risk reduction, and approved therapy classes. https://pubmed.ncbi.nlm.nih.gov/34448749/
  17. 35797481 — The 2022 hormone therapy position statement of The North American Menopause Society — MHT benefit-risk framing and prevention of bone loss/fracture. https://pubmed.ncbi.nlm.nih.gov/35797481/
  18. 35594133 — Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2 — ACOG osteoporosis treatment guidance. https://pubmed.ncbi.nlm.nih.gov/35594133/
  19. 28426619 — ACOG Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency — hormone therapy to reduce osteoporosis risk in primary ovarian insufficiency. https://pubmed.ncbi.nlm.nih.gov/28426619/
  20. NIAMS — Osteoporosis: Diagnosis, Treatment, and Steps to Take — DXA, diagnosis, treatment, lifestyle, and medication overview. https://www.niams.nih.gov/health-topics/osteoporosis/diagnosis-treatment-and-steps-to-take
  21. Mayo Clinic — Osteoporosis: Symptoms and causes — risk factors and symptoms. https://www.mayoclinic.org/diseases-conditions/osteoporosis/symptoms-causes/syc-20351968
  22. Cleveland Clinic — DEXA Scan / Bone Density Test — patient-facing DXA explanation. https://my.clevelandclinic.org/health/diagnostics/10683-dexa-dxa-scan-bone-density-test
  23. Cleveland Clinic — Osteoporosis — patient-facing signs, fracture clues, and evaluation prompts. https://my.clevelandclinic.org/health/diseases/4443-osteoporosis
  24. FDA label — Evista / raloxifene — FDA-approved SERM indication for postmenopausal osteoporosis. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020815s034lbl.pdf
  25. FDA label — Prolia / denosumab — FDA label for denosumab in postmenopausal osteoporosis at high fracture risk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125320s216lbl.pdf

FAQ